Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
Authors
Keywords
-
Journal
Nature Communications
Volume 10, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-03-26
DOI
10.1038/s41467-019-09068-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients
- (2018) Oliver A. Zill et al. CLINICAL CANCER RESEARCH
- Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies
- (2018) Justin I. Odegaard et al. CLINICAL CANCER RESEARCH
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic profiling of ER + breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance
- (2017) Jennifer M. Giltnane et al. Science Translational Medicine
- ATRX is a regulator of therapy induced senescence in human cells
- (2017) Marta Kovatcheva et al. Nature Communications
- Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer
- (2016) Maria Teresa Herrera-Abreu et al. CANCER RESEARCH
- The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis
- (2016) D. G. Stover et al. CLINICAL CANCER RESEARCH
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt
- (2016) Jinfang Zhang et al. MOLECULAR CELL
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
- (2016) C Yang et al. ONCOGENE
- Polyclonal SecondaryFGFR2Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
- (2016) Lipika Goyal et al. Cancer Discovery
- Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities
- (2016) Jorge Franco et al. Cell Reports
- Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
- (2015) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
- (2015) Rinath Jeselsohn et al. Nature Reviews Clinical Oncology
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition
- (2015) Marta Kovatcheva et al. Oncotarget
- Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
- (2015) Richard B. Lanman et al. PLoS One
- CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer
- (2015) Jorge Franco et al. Oncotarget
- Socrates: identification of genomic rearrangements in tumour genomes by re-aligning soft clipped reads
- (2014) Jan Schröder et al. BIOINFORMATICS
- CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors
- (2014) Sadhna R. Vora et al. CANCER CELL
- The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes
- (2014) Sabine Paternot et al. CELL CYCLE
- GSVA: gene set variation analysis for microarray and RNA-Seq data
- (2013) Sonja Hänzelmann et al. BMC BIOINFORMATICS
- Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
- (2013) Kristian Cibulskis et al. NATURE BIOTECHNOLOGY
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- PD01-01: Randomized Phase II Trial of Fulvestrant with or without Dasatinib in Postmenopausal Patients with Hormone Receptor-Positive Metastatic Breast Cancer Previously Treated with an Aromatase Inhibitor.
- (2012) GL Wright et al. CANCER RESEARCH
- PD01-02: Randomized Phase II Study of Dasatinib vs Placebo in Addition to Exemestane in Advanced ER/PR-Positive Breast Cancer [BMS CA180-261 Study].
- (2012) A Llombart et al. CANCER RESEARCH
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features
- (2012) Sara A. Byron et al. PLoS One
- E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models
- (2011) Ezia Bello et al. CANCER RESEARCH
- Four faces of cellular senescence
- (2011) Francis Rodier et al. JOURNAL OF CELL BIOLOGY
- A framework for variation discovery and genotyping using next-generation DNA sequencing data
- (2011) Mark A DePristo et al. NATURE GENETICS
- A public genome-scale lentiviral expression library of human ORFs
- (2011) Xiaoping Yang et al. NATURE METHODS
- Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts
- (2010) K. Michaud et al. CANCER RESEARCH
- FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
- (2010) N. Turner et al. CANCER RESEARCH
- The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
- (2010) A. McKenna et al. GENOME RESEARCH
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
- (2010) J L Dean et al. ONCOGENE
- Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads
- (2009) K. Ye et al. BIOINFORMATICS
- Fast and accurate short read alignment with Burrows-Wheeler transform
- (2009) H. Li et al. BIOINFORMATICS
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis
- (2009) S S Kwek et al. ONCOGENE
- The Precise Sequence of FGF Receptor Autophosphorylation Is Kinetically Driven and Is Disrupted by Oncogenic Mutations
- (2009) E. D. Lew et al. Science Signaling
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now